189 related articles for article (PubMed ID: 14644393)
1. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia.
Caslake MJ; Stewart G; Day SP; Daly E; McTaggart F; Chapman MJ; Durrington P; Laggner P; Mackness M; Pears J; Packard CJ
Atherosclerosis; 2003 Dec; 171(2):245-53. PubMed ID: 14644393
[TBL] [Abstract][Full Text] [Related]
2. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
3. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
Vergès B; Florentin E; Baillot-Rudoni S; Monier S; Petit JM; Rageot D; Gambert P; Duvillard L
Diabetologia; 2008 Aug; 51(8):1382-90. PubMed ID: 18535816
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome.
Ooi EM; Barrett PH; Chan DC; Nestel PJ; Watts GF
Atherosclerosis; 2008 Mar; 197(1):139-46. PubMed ID: 17416370
[TBL] [Abstract][Full Text] [Related]
5. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.
Otokozawa S; Ai M; Van Himbergen T; Asztalos BF; Tanaka A; Stein EA; Jones PH; Schaefer EJ
Atherosclerosis; 2009 Jul; 205(1):197-201. PubMed ID: 19200542
[TBL] [Abstract][Full Text] [Related]
6. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
7. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
9. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects.
Marcoux C; Tremblay M; Fredenrich A; Jacques H; Krimbou L; Nakajima K; Davignon J; Cohn JS
Atherosclerosis; 1998 Jul; 139(1):161-71. PubMed ID: 9699904
[TBL] [Abstract][Full Text] [Related]
10. The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes.
Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
Atherosclerosis; 2004 May; 174(1):141-9. PubMed ID: 15135263
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
[TBL] [Abstract][Full Text] [Related]
12. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.
Rizos CV; Liberopoulos EN; Tellis CC; Florentin M; Elisaf MS; Tselepis AD
Metab Syndr Relat Disord; 2011 Jun; 9(3):217-23. PubMed ID: 21352079
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
[TBL] [Abstract][Full Text] [Related]
15. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
[TBL] [Abstract][Full Text] [Related]
17. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
18. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
Olsson AG; Pears J; McKellar J; Mizan J; Raza A
Am J Cardiol; 2001 Sep; 88(5):504-8. PubMed ID: 11524058
[TBL] [Abstract][Full Text] [Related]
19. Is hypertriglyceridemic very low density lipoprotein a precursor of normal low density lipoprotein?
Oschry Y; Olivecrona T; Deckelbaum RJ; Eisenberg S
J Lipid Res; 1985 Feb; 26(2):158-67. PubMed ID: 3989374
[TBL] [Abstract][Full Text] [Related]
20. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia.
Yang CY; Gu ZW; Xie YH; Valentinova NV; Yang M; Yeshurun D; Quion JA; Gotto AM
Atherosclerosis; 1996 Sep; 126(1):105-16. PubMed ID: 8879439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
